Currently, there are various types of drugs for the treatment of chronic heart failure in the world, such as angiotensin receptor-neprilysin inhibitors, ACE inhibitors, angiotensin II receptor antagonists, beta-blockers, aldosterone antagonists, sodium-glucose cotransporter 2 inhibitors, soluble guanylate cyclase stimulators, ivabradine, digitalis drugs, cardiac resynchronization therapy, and implantable cardioverter-defibrillators, etc. Despite increasingly novel treatment regimens, the mortality rate and rehospitalization rate of chronic heart failure remains high (5, 6). This evidence concerns the gene ACE and congestive heart failure.